Health Condition 1: null- none specific
Conditions
Interventions
Intervention1: Neostigmine: 30 mcg/kg IV at the end of surgery
Intervention2: neostigmine: 40 mcg/kg
Intervention3: Neostigmine: 50 mcg/kg
Intervention4: Neostigmine: 40 mcg/kg at the end of surgery
I
Sponsors
none
Eligibility
Inclusion criteria
Inclusion criteria: BMI 30-40 kg/m2 undergoing elective surgery of expected duration less than or equal to 3 hours under general anesthesia
Exclusion criteria
Exclusion criteria: history of neuromuscular diseases, hepatic or renal disorders history of use of drugs known to influence neuromuscular transmission history of allergic reactions to any of the drugs pregnancy patients for proposed elective postoperative ventilation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time taken in seconds for reversal to TOF ratio of 0.5, 0.7 and 0.9Timepoint: time taken in seconds for reversal to TOF ratio of 0.5, 0.7 and 0.9 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Cumulative dose of vecuronium used 2.Lag time (s) from the time of bolus injection of vecuronium to the beginning of depression of T1 3.Onset time (min) from the injection of vecuronium to maximum depression of T1 4.Duration (min) from the injection of vecuronium to spontaneous recovery of T1 to 25% of control (DUR25%) 5.TOF ratio at administration of reversal in all three groups 6.Clinical muscle function tests 7.Evaluation of consciousness 8.Adverse events Timepoint: parameters 1-5: as measured by neuromuscular monitor parameters 6-8: immediately after extubation and every 15 minutes upto 1 hour | — |
Countries
India
Contacts
Public ContactKausalya V
JIPMER
Outcome results
None listed